Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Other Non-Current Liabilities (2019 - 2021)

Historic Other Non-Current Liabilities for Nurix Therapeutics (NRIX) over the last 3 years, with Q3 2021 value amounting to $796000.0.

  • Nurix Therapeutics' Other Non-Current Liabilities fell 829.49% to $796000.0 in Q3 2021 from the same period last year, while for Aug 2021 it was $796000.0, marking a year-over-year decrease of 829.49%. This contributed to the annual value of $850000.0 for FY2020, which is 5106.51% down from last year.
  • According to the latest figures from Q3 2021, Nurix Therapeutics' Other Non-Current Liabilities is $796000.0, which was down 829.49% from $837000.0 recorded in Q2 2021.
  • In the past 5 years, Nurix Therapeutics' Other Non-Current Liabilities ranged from a high of $1.7 million in Q4 2019 and a low of $796000.0 during Q3 2021
  • In the last 3 years, Nurix Therapeutics' Other Non-Current Liabilities had a median value of $843500.0 in 2020 and averaged $986666.7.
  • Per our database at Business Quant, Nurix Therapeutics' Other Non-Current Liabilities crashed by 5106.51% in 2020 and then plummeted by 829.49% in 2021.
  • Over the past 3 years, Nurix Therapeutics' Other Non-Current Liabilities (Quarter) stood at $1.7 million in 2019, then tumbled by 51.07% to $850000.0 in 2020, then decreased by 6.35% to $796000.0 in 2021.
  • Its Other Non-Current Liabilities was $796000.0 in Q3 2021, compared to $837000.0 in Q2 2021 and $832000.0 in Q1 2021.